Adrian W. Messerli, MD Department of Cardiovascular Medicine, The Cleveland Clinic
Herbert D. Aronow, MD, MPH Department of Cardiovascular Medicine, The Cleveland Clinic
Dennis L. Sprecher, MD Adjunct staff, The Cleveland Clinic; Director, Dyslipidemia, Discovery Medicine, GlaxoSmithKline; formerly head, Section of Cardiac Prevention, Department of Cardiovascular Medicine, The Cleveland Clinic
Address: Dennis Sprecher, MD, GlaxoSmithKline, 709 Swedelan Rd, UW2900, King of Prussia, PA 19406
Dr. Aronow has indicated that he serves as a consultant for and is on the speaker’s bureau of the Pfizer corporation.
Dr. Sprecher became employed by GlaxoSmithKline corporation after this paper was written and accepted.
This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.
ABSTRACTThe Lescol Intervention Prevention Study (LIPS) was the first randomized trial to show a significant reduction in the risk of cardiac events in patients started on fluvastatin immediately after a successful percutaneous coronary intervention. The benefit was independent of baseline cholesterol levels. The results suggest that all patients should be discharged on lipid-lowering therapy after a percutaneous coronary intervention. Currently, this is seldom done.
